• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Daratumumab, Venetoclax, and Azacitidine in Combination with the HAA Regimen as Consolidation Chemotherapy for T-Cell Acute Lymphoblastic Leukemia with High CD38 Expression.达雷妥尤单抗、维奈克拉和阿扎胞苷联合HAA方案作为巩固化疗用于治疗高表达CD38的T细胞急性淋巴细胞白血病
Turk J Haematol. 2025 Aug 29;42(3):232-234. doi: 10.4274/tjh.galenos.2025.2025.0019. Epub 2025 May 6.
2
Venetoclax-Based Regimen in Refractory or Relapsed Pediatric Acute Lymphoblastic Leukemia.基于维奈托克的方案用于难治性或复发性小儿急性淋巴细胞白血病
Acta Haematol. 2025 Jul 8:1-7. doi: 10.1159/000547080.
3
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.一项在门诊环境中进行的 Venetoclax 联合阿扎胞苷或地西他滨治疗急性髓系白血病患者的 3b 期研究。
Hematol Oncol. 2024 May;42(3):e3274. doi: 10.1002/hon.3274.
4
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.强化或低强度诱导后急性髓系白血病患者采用小剂量阿扎胞苷联合维奈托克作为维持治疗的单中心、单臂、2 期临床试验。
Lancet Haematol. 2024 Apr;11(4):e287-e298. doi: 10.1016/S2352-3026(24)00034-6.
5
Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia.ivosidenib与其他疗法在新诊断急性髓系白血病患者中的间接治疗比较。
Future Oncol. 2025 Jul;21(17):2225-2235. doi: 10.1080/14796694.2025.2515778. Epub 2025 Jun 10.
6
Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis.阿扎胞苷、维奈克拉和玛格罗利单抗用于新诊断及复发难治性急性髓系白血病：1b/2期研究及相关分析
Clin Cancer Res. 2025 Apr 8. doi: 10.1158/1078-0432.CCR-25-0229.
7
Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma.达雷妥尤单抗联合硼替佐米及地塞米松用于难治性T细胞淋巴母细胞淋巴瘤异基因移植的过渡治疗
Ann Hematol. 2025 Jun 26. doi: 10.1007/s00277-025-06474-z.
8
Safety and Efficacy of Grapefruit Juice Combined With Low-Dose Venetoclax in AML Patients Ineligible for Intensive Chemotherapy.葡萄柚汁联合低剂量维奈克拉在不符合强化化疗条件的急性髓系白血病患者中的安全性和有效性
Clin Ther. 2025 Aug;47(8):595-601. doi: 10.1016/j.clinthera.2025.05.008. Epub 2025 Jun 13.
9
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
10
Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.不适合标准诱导化疗的急性髓细胞白血病患者的治疗方法：系统评价。
Future Oncol. 2023 Apr;19(11):789-810. doi: 10.2217/fon-2022-1286. Epub 2023 May 12.

本文引用的文献

1
Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.长期暴露于阿扎胞苷及对造血干细胞移植后早期T细胞前体急性淋巴细胞白血病复发的反应：一例报告并文献复习
Leuk Lymphoma. 2024 Dec;65(13):2025-2030. doi: 10.1080/10428194.2024.2390572. Epub 2024 Aug 14.
2
The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience.基于达雷妥尤单抗的方案治疗复发/难治性急性白血病的临床疗效：单中心经验。
Ann Hematol. 2024 Oct;103(10):4057-4063. doi: 10.1007/s00277-024-05892-9. Epub 2024 Jul 24.
3
Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia.高三尖杉酯碱可能有助于改善 AML1-ETO 阳性急性髓系白血病患者中维奈托克和阿扎胞苷的疗效。
J Cancer Res Clin Oncol. 2024 Jul 6;150(7):336. doi: 10.1007/s00432-024-05861-9.
4
Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia.高三尖杉酯碱抑制 NOTCH/MYC 通路并在 T 细胞急性淋巴细胞白血病中发挥抗肿瘤作用。
Blood. 2024 Sep 19;144(12):1343-1347. doi: 10.1182/blood.2023023400.
5
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.达雷妥尤单抗与维奈克拉联合 CAGE 方案治疗晚期复发/难治性 T 细胞急性淋巴细胞白血病/淋巴母细胞淋巴瘤患者：单臂、开放标签、I 期研究。
Ann Hematol. 2024 Aug;103(8):2993-3004. doi: 10.1007/s00277-024-05775-z. Epub 2024 Apr 25.
6
The role of daratumumab in relapsed/refractory CD38 positive acute leukemias-case report on three cases with a literature review.达雷妥尤单抗在复发/难治性CD38阳性急性白血病中的作用——三例病例报告及文献综述
Front Oncol. 2023 Oct 24;13:1228481. doi: 10.3389/fonc.2023.1228481. eCollection 2023.
7
Frequent, high density expression of surface CD38 as a potential therapeutic target in adult T-lineage acute lymphoblastic leukemia.表面CD38频繁、高密度表达作为成人T淋巴细胞系急性淋巴细胞白血病的潜在治疗靶点。
Haematologica. 2024 Feb 1;109(2):661-665. doi: 10.3324/haematol.2023.283814.
8
Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.阿糖胞苷和高三尖杉酯碱（HAA）与阿糖胞苷和伊达比星（IA）方案作为初治核心结合因子急性髓系白血病患者诱导治疗的疗效比较。
Ann Hematol. 2023 Oct;102(10):2695-2705. doi: 10.1007/s00277-023-05400-5. Epub 2023 Aug 12.
9
CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.不同启动子驱动的 CD38 特异性 CAR 整合到 CD38 基因座可导致 T 和 NK 细胞产生不同的抗肿瘤活性。
Adv Sci (Weinh). 2023 Sep;10(27):e2207394. doi: 10.1002/advs.202207394. Epub 2023 Jul 23.
10
Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review.维奈克拉联合 CAG 方案治疗早幼粒细胞性急性淋巴细胞白血病 1 例报告并文献复习
Int J Hematol. 2023 Oct;118(4):483-488. doi: 10.1007/s12185-023-03623-w. Epub 2023 Jun 3.

Daratumumab, Venetoclax, and Azacitidine in Combination with the HAA Regimen as Consolidation Chemotherapy for T-Cell Acute Lymphoblastic Leukemia with High CD38 Expression.

作者信息

Feng Lin-Sen, Li Hui-Yuan, Tang Ai, Xu Meng-Li, Wang San-Bin

机构信息

The Sixth Affiliated Hospital, Kunming Medical University, Department of Hematology, Yunnan, P.R. China

The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, P.R. China

出版信息

Turk J Haematol. 2025 Aug 29;42(3):232-234. doi: 10.4274/tjh.galenos.2025.2025.0019. Epub 2025 May 6.

DOI:10.4274/tjh.galenos.2025.2025.0019
PMID:40326525
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12400890/
Abstract
摘要